journal article·2026-02Open access

Emerging strategies for advancing peptide vaccines

Yuan Luo, Shiqi Zhou, Shengjia Wu, Honglin Jin, Jonathan F. Lovell

Cell Reports Physical Science· Volume 7· Issue 2

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: vaccines and immunoinformatics approaches · Immunotherapy and Immune Responses · Bacterial Infections and Vaccines

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites10.1038/328257a0 ↗
2. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial10.1016/j.vaccine.2012.04.089 ↗
3. Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection10.1016/j.clim.2012.12.005 ↗
4. Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study10.1016/j.ebiom.2023.104665 ↗
5. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial10.1016/S1470-2045(14)70236-0 ↗
6. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma10.1038/nm0398-321 ↗
7. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides10.1016/0092-8674(86)90019-X ↗
8. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma10.1126/science.1840703 ↗
9. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine
10. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene10.1126/science.2999974 ↗
11. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene10.1126/science.3798106 ↗
12. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes10.1084/jem.179.3.1005 ↗
13. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma10.1038/nm0897-917 ↗
14. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization10.1016/S0092-8674(00)80538-3 ↗
15. Peptide Delivery Systems for Cancer Vaccines10.1002/adtp.201800060 ↗
16. Life-Threatening Infections Due to Live-Attenuated Vaccines: Early Manifestations of Inborn Errors of Immunity10.1007/s10875-019-00642-3 ↗
17. Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naive and PD-1 antibody-experienced patients with melanoma (MEL64)10.1136/jitc-2022-005424 ↗
18. Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial10.1158/1078-0432.CCR-18-2867 ↗
19. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial10.1016/S1470-2045(16)30408-9 ↗
20. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial10.1016/S1470-2045(17)30517-X ↗
21. Expanding roles for CD4(+) T cells in immunity to viruses10.1038/nri3152 ↗
22. Tumor-specific CD4+ T cells have a major “post-licensing” role in CTL mediated anti-tumor immunity10.4049/jimmunol.165.11.6047 ↗
23. Evolution of molluscan hemocyanin structures10.1016/j.bbapap.2013.02.020 ↗
24. Keyhole Limpet Haemocyanin in Experimental Bladder CancerLiterature Review and Own Results10.1159/000052390 ↗
25. Evaluation of human antibody responses to keyhole limpet hemocyanin on a carbohydrate microarray10.1002/prca.200900130 ↗
26. Dendritic cell KLH loading requirements for efficient CD4+ T-cell priming and help to peptide-specific cytotoxic T-cell response, in view of potential use in cancer vaccines10.1016/S0264-410X(02)00534-0 ↗
27. Targeted Delivery of Personalized Cancer Vaccines Based on Antibody-Antigen Complexes10.3390/vaccines13030324 ↗
28. A Novel Abeta B-cell epitope Vaccine, Abeta1-10 with carrier protein OVA and KLH reduce Abeta-induced neuroinflammation mediated neuropathology in mouse model of Alzheimer's disease10.1016/j.bbi.2025.06.001 ↗
29. Keyhole limpet haemocyanin - a model antigen for human immunotoxicological studies10.1111/bcp.12422 ↗
30. Protein carriers of conjugate vaccines: characteristics, development, and clinical trials10.4161/hv.26109 ↗
31. Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use10.1016/j.vaccine.2010.04.072 ↗
32. CRM197-conjugated multi antigen dominant epitope for effective human cytomegalovirus vaccine development10.1016/j.ijbiomac.2022.10.105 ↗
33. CRM197-conjugated peptides vaccine of HCMV pp65 and gH induce maturation of DC and effective viral-specific T cell responses10.1080/21505594.2023.2169488 ↗
34. Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)10.1158/1078-0432.CCR-24-0742 ↗
35. Carrier priming effect of CRM197 is related to an enhanced B and T cell activation in meningococcal serogroup A conjugate vaccination. Immunological comparison between CRM197 and diphtheria toxoid10.1016/j.vaccine.2016.03.055 ↗
36. Diphtheria-tetanus-pertussis vaccine: past, current & future10.2217/fmb-2021-0167 ↗
37. Bystander stimulation of activated CD4+ T cells of unrelated specificity following a booster vaccination with tetanus toxoid10.1002/eji.200940017 ↗
38. Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement
39. Glycoconjugate vaccines and immune interference: A review10.1016/j.vaccine.2010.06.026 ↗
40. Effect of priming with carrier on response to conjugate vaccine10.1016/S0140-6736(89)92033-3 ↗
41. Serologic Immunity to Tetanus in the United States, National Health and Nutrition Examination Survey, 2015-201610.1093/cid/ciad598 ↗
42. Genetically detoxified tetanus toxin as a vaccine and conjugate carrier protein10.1016/j.vaccine.2022.07.011 ↗
43. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma10.1172/JCI162283 ↗
44. Virus-like particles: a versatile and effective vaccine platform10.1080/14760584.2025.2508517 ↗
45. Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide10.3390/vaccines8040765 ↗
46. A cholesterol-lowering VLP vaccine that targets PCSK910.1016/j.vaccine.2015.09.044 ↗
47. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-910.1016/j.antiviral.2017.09.012 ↗
48. Brief on Recent Application of Liposomal Vaccines for Lower Respiratory Tract Viral Infections: From Influenza to COVID-19 Vaccines
49. Development of Peptide-Based Vaccines for Cancer10.1155/2022/9749363 ↗
50. Liposome Formulations as Adjuvants for Vaccines
51. Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases10.1074/jbc.M110.186338 ↗
52. Vaccine approaches for antigen capture by liposomes10.1080/14760584.2023.2274479 ↗
53. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice10.1073/pnas.0703137104 ↗
54. Lipid-peptide bioconjugation through pyridyl disulfide reaction chemistry and its application in cell targeting and drug delivery10.1186/s12951-019-0509-8 ↗
55. Cell-Penetrating Peptides-Based Liposomal Delivery System Enhanced Immunogenicity of Peptide-Based Vaccine against Group A Streptococcus
56. Synthesis and evaluation of a novel adapter lipid derivative for preparation of cyclic peptide-modified PEGylated liposomes: Application of cyclic RGD peptide10.1016/j.ejps.2022.106239 ↗
57. Adjuvant system AS01: from mode of action to effective vaccines10.1080/14760584.2024.2382725 ↗
58. Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccine10.1172/jci.insight.163859 ↗
59. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older10.1056/NEJMoa1603800 ↗
60. Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants10.1038/s41541-021-00337-0 ↗
61. Recombinant Zoster Vaccine (Shingrix((R))): A Review in Herpes Zoster10.1007/s40266-018-0603-x ↗
62. RTS,S/AS01 vaccine (Mosquirix): an overview10.1080/21645515.2019.1669415 ↗
63. Ison · Lancet Respir. Med. · 2025 · 13 · 51710.1016/S2213-2600(25)00048-7 ↗
64. Liposomes physically coated with peptides: preparation and characterization10.1021/la501296r ↗
65. Electrostatically Driven Encapsulation of Hydrophilic, Non-Conformational Peptide Epitopes into Liposomes10.3390/pharmaceutics11110619 ↗
66. Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity10.1208/s12248-014-9686-4 ↗
67. Encapsulation of lipopeptides within liposomes: effect of number of lipid chains, chain length and method of liposome preparation10.1016/j.ijpharm.2005.06.010 ↗
68. Optimization of a Method to Prepare Liposomes Containing HER2/Neu- Derived Peptide as a Vaccine Delivery System for Breast Cancer
69. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens10.1016/j.vaccine.2012.01.070 ↗
70. Functionalization of cobalt porphyrin-phospholipid bilayers with his-tagged ligands and antigens10.1038/nchem.2236 ↗
71. Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids10.1016/S0005-2736(02)00618-1 ↗
72. Identification of Enhanced Vaccine Mimotopes for the p15E Murine Cancer Antigen10.1158/2767-9764.CRC-23-0384 ↗
73. Iterative selection of lipid nanoparticle vaccine adjuvants for rapid elicitation of tumoricidal CD8(+) T cells
74. An In Vivo Screen to Identify Short Peptide Mimotopes with Enhanced Antitumor Immunogenicity10.1158/2326-6066.CIR-21-0332 ↗
75. Self-assembling peptides: From a discovery in a yeast protein to diverse uses and beyond10.1002/pro.3951 ↗
76. Self-assemble peptide biomaterials and their biomedical applications
77. Harnessing self-assembled peptide nanoparticles in epitope vaccine design10.1016/j.biotechadv.2017.05.002 ↗
78. The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation10.1016/j.biomaterials.2013.07.063 ↗
79. A self-assembling peptide acting as an immune adjuvant10.1073/pnas.0912124107 ↗
80. Modulating adaptive immune responses to peptide self-assemblies10.1021/nn204530r ↗
81. Self-assembled peptide nanorod vaccine confers protection against influenza A virus10.1016/j.biomaterials.2021.120672 ↗
82. A Supramolecular Vaccine Platform Based on alpha-Helical Peptide Nanofibers10.1021/acsbiomaterials.7b00561 ↗
83. Multiepitope supramolecular peptide nanofibers eliciting coordinated humoral and cellular antitumor immune responses10.1126/sciadv.abm7833 ↗
84. A powerful CD8+ T-cell stimulating D-tetra-peptide hydrogel as a very promising vaccine adjuvant10.1002/adma.201601776 ↗
85. A versatile supramolecular nanoadjuvant that activates NF-κB for cancer immunotherapy10.7150/thno.34031 ↗
86. Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy10.1016/j.actbio.2022.12.070 ↗
87. Rigid helical-like assemblies from a self-aggregating tripeptide10.1038/s41563-019-0343-2 ↗
88. A Modular Self-Assembling and Self-Adjuvanting Multiepitope Peptide Nanoparticle Vaccine Platform to Improve the Efficacy and Immunogenicity of BCG
89. Vaccine adjuvants: Tailoring innate recognition to send the right message10.1016/j.immuni.2024.03.015 ↗
90. Peptide emulsions in incomplete Freund's adjuvant create effective nurseries promoting egress of systemic CD4(+) and CD8(+) T cells for immunotherapy of cancer10.1136/jitc-2022-004709 ↗
91. Safety data of Montanide ISA 51 VG and Montanide ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines
92. Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study10.1158/1078-0432.CCR-22-0112 ↗
93. Safety and tolerability evaluation of the use of Montanide ISA™ 51 as vaccine adjuvant: A systematic review10.1080/21645515.2015.1071455 ↗
94. Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant10.1186/1479-5876-4-42 ↗
95. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches10.1038/s41577-020-0357-7 ↗
96. GM-CSF: A Double-Edged Sword in Cancer Immunotherapy10.3389/fimmu.2022.901277 ↗
97. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients10.1093/annonc/mdl158 ↗
98. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence10.1093/annonc/mdw150 ↗
99. Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients10.1245/s10434-017-5844-0 ↗
100. A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy10.1186/s13046-021-02017-2 ↗